Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.39 |
| ▸ | ADK | P55263 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 2/20 | 0.35 |
| ▸ | NEK7 | Q8TDX7 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23630540 | 1.00 | MEN1 (0.40) | MEN1KMT2APRKD3ADKKCNH2 | |
| SCHEMBL23630578 | 0.93 | MEN1 (0.40) | MEN1KMT2APRKD3ADKKCNH2 | |
| SCHEMBL32659764 | 0.93 | MEN1 (0.40) | MEN1KMT2APRKD3ADKKCNH2 | |
| SCHEMBL32659761 | 0.92 | MEN1 (0.40) | MEN1KMT2APRKD3ADKKCNH2 | |
| SCHEMBL23630553 | 0.92 | MEN1 (0.40) | MEN1KMT2APRKD3ADKKCNH2 | |
| SCHEMBL23630548 | 0.91 | PRKD3 (0.41) | MEN1KMT2APRKD3ADKKCNH2 | |
| SCHEMBL32659781 | 0.91 | PRKD3 (0.41) | MEN1KMT2APRKD3ADKKCNH2 | |
| SCHEMBL23630545 | 0.91 | MAPT (0.43) | MEN1KMT2AADKKCNH2MAPT | |
| SCHEMBL32659773 | 0.91 | MAPT (0.43) | MEN1KMT2AADKKCNH2MAPT | |
| SCHEMBL23630582 | 0.90 | PRKD3 (0.42) | MEN1KMT2APRKD3ADKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522606-B2 | Modified pyrrolo- and pyrazolo-pyrimidines for prostate cancer therapy | UNIVERSITY OF WASHINGTON (US) | 2026-01-13 | — | — | US | claimed |